Save Page settings
IBM Clinical Development
Product Enhancements
Customer-driven improvements designed to enhance user experience
Learn more today
Transformational healthcare solutions from Truven Health Analytics®, now offered by IBM Watson Health.
Resource Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Resource Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Resource Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Query Management Enhancement
The IBM® Clinical Development team is pleased to release a solution enhancement that offers a number of updates based on ongoing client feedback and changing needs.

Our latest enhancement has streamlined the entire query management workflow to improve your day to day.
Learn more
Resource Type

Watson is helping Barrow Neurological Institute identify 5 new proteins linked to amyotrophic lateral sclerosis (ALS)


Watch the video
Resource Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
Watch the video
Simplified queries via new features
With IBM Clinical Development, you can gather, organize, analyze and report data for any type, size or phase of trial anywhere in the world.
Learn more
Simplified queries via new features
subheading
To reduce the complexity of the query process, you can now add queries, access their history, update their status, and more, via a pop-up dialogue box directly on the CRF page.

You now have access to your Query task list with just one click on a Ticker directly from the landing page. Additionally, within the Query Metrics report, you have the ability to update the status of multiple queries simultaneously. The new reporting format is designed to offer better filtering, sorting, search and more. 
CTA Label
Drug Repurposing
Vadem te ad mortem tyranno dabis pro amico
Let Watson for Drug Discovery answer your Questions...

CTA Label
Page status enhancements
Enjoy increased flexibility by choosing to activate additional page status auto-updates. Further customize your study design with new capabilities around page status permissions. 
CTA Label
Improved team management capabilities
Team managers have access to a new central report that empowers them with more visibility and control over all user accounts across multiple studies.
CTA Label
Flexible Pricing
You can now add queries, access their history, update their status, and more, via a pop-up dialogue box directly on the CRF page.

  • Access to your Query task list with just one click on a Ticker directly from the landing page. 
  • Within the Query Metrics report, update the status of multiple queries simultaneously.
  • The new reporting format is designed to offer better filtering, sorting, search and more. 


CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Heading copy iubet igitur
Body copy quod si ita sit, cur opera philosophiae sit danda nescio. Vadem te ad mortem tyranno dabis pro amico, ut Pythagoreus ille Siculo fecit tyranno.
CTA Label
Title
Expand your research targets using the power of Artificial Intelligence
Watson for Drug Discovery ingests millions of pieces data from Medline abstracts, patents to PMC Open Access articles and processes them using the latest Natural language processing (NLP) and AI  technology to deliver predicative relationships for researchers to identify novel drug targets and new indications.
CTA Label
Drug Target Identification
Using Artificial Intelligence & advanced Natural Language Processing (NLP) Watson will help you understand the disease & biological pathways to identify new gene targets & compounds as potential drug candidates.

Case Study
Watson for Drug Discovery is helping researchers at Barrow Neurological Institute identify new drug targets for ALS research.
Watch Video Now
Drug Repurposing
Watson's cognitive computing capabailities will help you build on earlier research and scale Drug Repurposing to an industrial level. It can eliminate bias and detect hidden connections that may not be seen by researchers to predict potential relationships for further evaluation.

Case Study
Watson for Drug Discovery Equipped University of Toronto with Cognitive Tools to Accelerate Drug Repurposing for Parkinson’s Disease.
Watch Video Now

Simplified queries via new features
You can now add queries, access their history, update their status, and more, via a pop-up dialogue box directly on the CRF page.

  • Access to your Query task list with just one click on a Ticker directly from the landing page. 
  • Within the Query Metrics report, update the status of multiple queries simultaneously.
  • The new reporting format is designed to offer better filtering, sorting, search and more. 



Page status enhancements
Enjoy increased flexibility by choosing to activate additional page status auto-updates. Further customize your study design with new capabilities around page status permissions. 


Improved team management capabilities
Team managers have access to a new central report that empowers them with more visibility and control over all user accounts across multiple studies.


Title
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
CTA Label
Card Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
CTA Label
Card Type
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos
CTA Label
Request a demo
Book a personal demo with our expert team by filling out the form and see for yourself how IBM Clinical Development can help transform the outcomes of your clinical trial.



Study start up as quickly as
4 days
to build a complete database including edit checks.


Heightened Confidence
23 of 25*
23 of the top 25 pharma have conducted trials on IBM Clinical Development


Global reach
30 languages
supported languages to scale with your global trials and patient populations


Expertise
20+ years
industry experience in clinical trials


*Based upon top pharmaceutical companies' 2014 revenue and current system usage




Fill out the form to get started today.
Event details title
calendar January 1, 2010
time 10:00 AM - 11:00 AM PST
person John Doe
"We simply would not have and could not have accomplish the research we did without WDD. The approach itself would not have been feasible and the labor intensiveness would have been too great."
-Dr. Naomi Visanji,
Scientist, University Health Network


"Watson now has uncovered five new proteins, RNA binding proteins that are changed in patients with ALS."
Dr. Robert Bowser, PhD
Professor and Chairman of Neuroscience, Barrow Neurological Institute
What are some genes that might be regulated by gene X?
John Doe,
ille Siculo fecit
What other indications are there for this known target?
John Doe,
ille Siculo fecit
What other biological pathways does this  drug/compound/target impact?
John Doe,
ille Siculo fecit
Transformational healthcare solutions from Truven Health Analytics®, now offered by IBM Watson Health.
APOLLO NOSCERE NOSMET
Heading copy iubet igitur nos Pythius Apollo noscere nosmet ipsos danda nescio
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
CTA Label
With IBM Clinical Development, you can gather, organize, analyze and report data for any type, size or phase of trial anywhere in the world.
Learn more
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.
Utram tandem linguam nescio? Igitur ne dolorem quidem. Nemo igitur esse beatus potest. Facillimum id quidem est, inquam. Bonum patria: miserum exilium. Iam contemni non poteris.